Solta Medical price target lowered to $4 from $5 at Cantor

theflyonthewall.com

After Solta reported lower than expected revenue and reduced its 2013 revenue guidance, Cantor thinks that gains in the stock may be limited in the near-term. The firm, however, keeps a Buy rating on the shares.

View Comments (0)